Matthew T. Breneman
YOU?
Author Swipe
View article: Transcriptomic Signatures of Monocyte‐Derived Macrophages Associate With Androgen Receptor Pathway Inhibitor Progression in Prostate Cancer
Transcriptomic Signatures of Monocyte‐Derived Macrophages Associate With Androgen Receptor Pathway Inhibitor Progression in Prostate Cancer Open
Background Androgen receptor pathway inhibitors (ARPIs) have significantly improved clinical outcomes for patients with metastatic prostate cancer (PC) but acquired ARPI resistance remains universal. Maximizing ARPI treatment duration is c…
View article: 1385 Dynamic reciprocal interactions between activated T cells and tumor associated macrophages drive macrophage repolarization and proinflammatory T cell migration within prostate tumor models
1385 Dynamic reciprocal interactions between activated T cells and tumor associated macrophages drive macrophage repolarization and proinflammatory T cell migration within prostate tumor models Open
View article: Dynamic reciprocal interactions between activated T cells and tumor associated macrophages drive macrophage reprogramming and proinflammatory T cell migration within prostate tumor models
Dynamic reciprocal interactions between activated T cells and tumor associated macrophages drive macrophage reprogramming and proinflammatory T cell migration within prostate tumor models Open
Tumor-associated macrophages (TAMs) have been implicated as a tumor microenvironment (TME) cell population, which may be playing a vital role in the inhibition of effective T cell responses in the prostate TME. In this manuscript, we lever…
View article: Data from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein
Data from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein Open
Cancer-associated fibroblasts (CAF) are a prominent cell type within the tumor microenvironment (TME) where they are known to promote cancer cell growth and survival, angiogenesis, drug resistance, and immunosuppression. The transmembrane …
View article: FIGURE 5 from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein
FIGURE 5 from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein Open
Downstream effects of huB12-MMAE treatment on gene expression in CAF-tumor models in Stacks. A, Concentration of selected factors in supernatant in monoculture and coculture conditions. B, Relative mRNA expression of select g…
View article: Supplementary Figure 1 from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein
Supplementary Figure 1 from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein Open
Antibody Humanization
View article: Supplementary Figure 2 from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein
Supplementary Figure 2 from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein Open
ADC efficacy in multiple cell lines
View article: Supplementary Figure 2 from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein
Supplementary Figure 2 from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein Open
ADC efficacy in multiple cell lines
View article: FIGURE 4 from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein
FIGURE 4 from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein Open
Specificity of huB12-MMAE treatment in the Stacks. A, Workflow of treatment and analysis of CAF-tumor models using huB12-MMAE. B, Viability analysis of CAFS (hPrCSC-44/top) and tumor cells (22Rv1/bottom) in monoculture (left)…
View article: Supplementary Figure 6 from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein
Supplementary Figure 6 from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein Open
mRNA expression of cytokines
View article: FIGURE 4 from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein
FIGURE 4 from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein Open
Specificity of huB12-MMAE treatment in the Stacks. A, Workflow of treatment and analysis of CAF-tumor models using huB12-MMAE. B, Viability analysis of CAFS (hPrCSC-44/top) and tumor cells (22Rv1/bottom) in monoculture (left)…
View article: Supplementary Figure 1 from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein
Supplementary Figure 1 from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein Open
Antibody Humanization
View article: FIGURE 3 from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein
FIGURE 3 from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein Open
In vitro and in vivo therapeutic efficacy of huB12-MMAE. A, FAP-targeted ADCs show a potent and FAP-selective cytotoxic activity. Cell viability hPrCSC-44, CWR-R1FAP, PC3, and CWR-R1 cell lines. Cells were treated for …
View article: Supplementary Figure 4 from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein
Supplementary Figure 4 from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein Open
Proliferation and survival marker gene expression
View article: Supplementary Figure 5 from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein
Supplementary Figure 5 from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein Open
VEGFA expression
View article: FIGURE 1 from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein
FIGURE 1 from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein Open
HuB12 internalizes into FAP-expressing cells. A, Confocal microscopy images of hPrCSC-44 cells (top) or PC3 cells (bottom) after incubation with Alexa Fluor-647 (AF647)-labeled huB12 (50 nmol/L) for 1 hour. Single-channel images of …
View article: FIGURE 3 from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein
FIGURE 3 from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein Open
In vitro and in vivo therapeutic efficacy of huB12-MMAE. A, FAP-targeted ADCs show a potent and FAP-selective cytotoxic activity. Cell viability hPrCSC-44, CWR-R1FAP, PC3, and CWR-R1 cell lines. Cells were treated for …
View article: Supplementary Figure 6 from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein
Supplementary Figure 6 from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein Open
mRNA expression of cytokines
View article: Supplementary Figure 3 from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein
Supplementary Figure 3 from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein Open
Determining the therapeutic window in the Stacks
View article: FIGURE 2 from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein
FIGURE 2 from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein Open
PET/CT imaging of FAP in vivo. A, Representative PET/CT images of mice bearing subcutaneous 22Rv1/hPrCSC-44 xenografts (white arrowhead). Mice (n = 3/group) received 3.5 MBq (25–50 µg, 7.7 µg/MBq) of [89Zr]Z…
View article: Supplementary Figure 4 from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein
Supplementary Figure 4 from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein Open
Proliferation and survival marker gene expression
View article: FIGURE 2 from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein
FIGURE 2 from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein Open
PET/CT imaging of FAP in vivo. A, Representative PET/CT images of mice bearing subcutaneous 22Rv1/hPrCSC-44 xenografts (white arrowhead). Mice (n = 3/group) received 3.5 MBq (25–50 µg, 7.7 µg/MBq) of [89Zr]Z…
View article: FIGURE 1 from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein
FIGURE 1 from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein Open
HuB12 internalizes into FAP-expressing cells. A, Confocal microscopy images of hPrCSC-44 cells (top) or PC3 cells (bottom) after incubation with Alexa Fluor-647 (AF647)-labeled huB12 (50 nmol/L) for 1 hour. Single-channel images of …
View article: Supplementary Figure 3 from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein
Supplementary Figure 3 from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein Open
Determining the therapeutic window in the Stacks
View article: Data from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein
Data from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein Open
Cancer-associated fibroblasts (CAF) are a prominent cell type within the tumor microenvironment (TME) where they are known to promote cancer cell growth and survival, angiogenesis, drug resistance, and immunosuppression. The transmembrane …
View article: FIGURE 5 from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein
FIGURE 5 from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein Open
Downstream effects of huB12-MMAE treatment on gene expression in CAF-tumor models in Stacks. A, Concentration of selected factors in supernatant in monoculture and coculture conditions. B, Relative mRNA expression of select g…
View article: Supplementary Figure 5 from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein
Supplementary Figure 5 from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein Open
VEGFA expression
View article: Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein
Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein Open
Cancer-associated fibroblasts (CAF) are a prominent cell type within the tumor microenvironment (TME) where they are known to promote cancer cell growth and survival, angiogenesis, drug resistance, and immunosuppression. The transmembrane …
View article: Integrated analysis of the tumor microenvironment using a reconfigurable microfluidic cell culture platform
Integrated analysis of the tumor microenvironment using a reconfigurable microfluidic cell culture platform Open
The tumor microenvironment (TME) is a complex network of non‐malignant cells and stroma that perform a wide array of vital roles in tumor growth, immune evasion, metastasis, and therapeutic resistance. These highly diverse roles have been …